RNA Manufacturing Resources

1. Advanced Therapies Going Mainstream: Are We There Yet? 11/14/2025

   Advanced therapies are nearing mainstream adoption, with cell, mRNA, and oligonucleotide treatments expanding into broader indications. Learn what’s driving this shift and what manufacturers must do.

2. How mRNA Technology Is Shaping The Future Of Medicine 1/4/2022

   Discover how mRNA technologies open the doors to a whole range of new gene therapies and the role of lipid nanoparticles (LNPs) in current and future developments.

3. Streamlining Biomanufacturing Automation With Connectivity And Integration 10/29/2023

   Gain insight into the recent advancements in connectivity and integration technology, the associated challenges, and the importance of a vendor-neutral approach.

4. Expectations On The Pathway To GMP For Gene-Modified Cell Therapies 6/21/2023

   Learn how a robust understanding of the RNP’s critical process parameters and CQAs is crucial for ensuring product consistency, enhancing patient safety, and maintaining regulatory compliance.

5. Process Development Considerations For RNA-LNP Therapeutics 9/13/2022

   Here, we highlight three important process considerations across the RNA-LNP manufacturing workflow which includes limit size behavior, in-line dilution and downstream tangential flow filtration (TFF).

6. How Is Additive Manufacturing Delivering On Sustainability Goals? 10/22/2024

   One of the key concerns for many biopharmaceutical companies is minimizing environmental impact. Learn about additive manufacturing and the significant advantages it offers to biomanufacturers.

7. Accelerated Development: Gene Therapy Vs. Small Molecule 12/26/2023

   Combined with the inherent difficulty of the chemistry behind gene therapy development, its pace, structure, and funding dynamics are unique among treatment modalities.

8. Changing The Status Quo Of Vaccine Production 3/2/2022

   Learn how the mRNA technology behind COVID-19 vaccines is poised to disrupt the status quo to improve global vaccine manufacturing capabilities.

9. Closed And Semi-Automated Processing Of CAR T Cells 7/5/2019

   Learn about a robust CAR T-cell manufacturing workflow that can be adapted for cGMP compliance in the commercial production of CAR T-cells.

10. Production And Clarification Of Lentiviral Vectors 10/30/2024

    Explore scalable processes for lentiviral vector production and clarification at the 50 L scale, utilizing the CTS LV-MAX system and single-use bioreactors for robust gene therapy manufacturing.